Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of January 2023, with the report dated January 3, 2023. The filing serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the company's total voting rights and capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data as of December 31, 2022.
- Issued Share Capital: 4,311,343,341 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 217,124,760 Ordinary Shares.
- Total Voting Rights: 4,094,218,581.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document reports a static snapshot of share capital as of the end of 2022 without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the statutory notification of voting rights to assist shareholders in determining notification requirements under FCA rules.
Important Facts for Investors to Verify
- Confirm the total number of voting rights (4,094,218,581) to calculate disclosure thresholds under FCA rules.
- Verify the number of shares held in Treasury (217,124,760) which are excluded from voting rights.
- Note that this filing contains no financial performance data; investors should refer to Form 20-F or other periodic reports for financial metrics.